Intelligence - PMLiVE
WEBOptimizing Patient Recruitment & Retention in Influenza Studies. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during the design phase.
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBPMLiVE | Pharmaceutical industry news, articles, jobs, reports, advice ... ... News
PME - PMLiVE
WEBPharmaceutical Market Europe – October 2023. Launch excellence – adapting to data disruption; preparing for the clinical trials of the future; the impact of cell therapies on cancer treatments.
Moderna shares positive late-stage results for COVID-19/flu …
WEBJun 11, 2024 · Moderna has shared positive late-stage results for its investigational combination vaccine against influenza and COVID-19. The ongoing phase 3 trial has been evaluating the candidate, mRNA-1083, in two age-group cohorts of …
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
FDA publishes new guidelines for COVID-19 vaccine approval
WEBOct 9, 2020 · FDA publishes new guidelines for COVID-19 vaccine approval. New rules mean a COVID-19 shot is unlikely to be approved pre-election in the US. The US Food and Drug Administration (FDA) has released new guidance detailing how it will grant emergency use authorisations (EUA) to COVID-19 vaccines. The most notable guideline to emerge from the FDA ...
Proving real-world value - PMLiVE
WEBSep 1, 2017 · Proving real-world value. The pharmaceutical industry’s focus on health outcomes has become a global movement. As payers negotiate reimbursement contracts based on patient outcomes and the concept of risk-sharing evolves, capturing the right data – from clinical studies, clinical practice and real-world experiences – has become critical.
FDA opens door to COVID-19 booster jabs - PMLiVE
WEBAug 16, 2021 · With the Delta variant of SARS-CoV-2 (B.1.617.2) gaining the upper hand across both the US and Europe, drug regulators have been looking at the data around booster shots.
COVID-19 vaccines against Omicron may be fast-tracked
WEBNov 30, 2021 · With cases of Omicron appearing across the world, it is clear that travel bans will not be enough to prevent the spread of the new SARS-CoV-2 variant of concern.
Communique - PMLiVE
WEBCommuniqué – Volume 53. New insights in health comms innovation. Communiqué Awards 2022 – winners’ case studies. INSIGHTS – Demonstrating impact • Driving behaviour change.
Skip to content